Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score

Ahmet Emre Eşkazan, Fehmı Tabak(Istanbul University-Cerrahpaşa), Seval Ürkmez(Türk Anesteziyoloji ve Reanimasyon Derneği), Seda Aladağ Kurt(Istanbul University-Cerrahpaşa), Kaan Can Demirbaş(Istanbul University-Cerrahpaşa), Devrim Sarıbal(Istanbul University-Cerrahpaşa), Nurgül Özgür Yurttaş(Istanbul University-Cerrahpaşa), Şermin Börekçi(Istanbul University-Cerrahpaşa), Kenan Midilli(Istanbul University-Cerrahpaşa), İ̇lker İnanç Balkan(Istanbul University-Cerrahpaşa), Güleren Yartaş Dumanlı(Istanbul University-Cerrahpaşa), Yalım Dikmen(Istanbul University-Cerrahpaşa), Mert Ahmet Kuşkucu(Istanbul University-Cerrahpaşa), Rıdvan Karaali(Tekirdağ Namık Kemal University), Yonca Sekibağ(Istanbul University-Cerrahpaşa), Ahmet Kurt(Istanbul University-Cerrahpaşa), Muhlis Cem Ar(Istanbul University-Cerrahpaşa), Işıl Bavunoğlu(Istanbul University), Bilgül Mete(Istanbul University-Cerrahpaşa), Sait Mulamahmutoğlu(Istanbul University-Cerrahpaşa), Gökhan Aygün(Istanbul University)
Journal of Infection and Chemotherapy
May 12, 2021
Cited by 11


Related Papers